News Prof Jonathan Benger named as NICE's new CEO Prof Jonathan Benger will take over from Dr Sam Roberts as CEO of UK reimbursement authority NICE later this week, at a critical time for the agency.
Market Access UK pharma policy at a turning point: NICE threshold reform, ... The ICER threshold increase is expected to allow an additional three to five medicines or indications each year to be recommended for NHS use.
News NHS use of digital cardiac rehab tools endorsed Seven digital health technologies used to support people recovering from cardiovascular diseases have been recommended for use by the NHS.
News UK and US agree zero tariffs on pharma – with price rises A deal between the UK and the US will maintain tariffs on imports into the US at 0%, but prices of medicines used by the NHS will go up.
News Wellcome donates £2m to UK's digital mental health drive Wellcome has provided £2m in additional funding to the MHRA and NICE for a project to build the use of digital mental health technologies in the NHS.
News Alnylam's ATTR cardiomyopathy drug backed for NHS use Patients with ATTR-CM in England and Wales will soon have a new treatment option, after NICE backed use of Alnylam's three-month injectable Amvuttra.
News J&J jumps on the MFN pricing train Johnson & Johnson is the latest pharma group to agree a Most-Favoured Nation (MFN) drug pricing deal with the Trump administration to avert tariffs.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.